PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025...

Key Manufacturing Milestone Strengthens PolyPid's Position as it Advances Towards Global Commercialization of D-PLEX Following Successful SHIELD II Phase 3 TrialPETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual...

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual...

PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, Deputy CEO, EVP R&D, Clinical, and Regulatory...

Positive Phase 3 SHIELD II Trial Results - D-PLEX successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI NDA submission expected in Q1 2026 Unveiled a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Obesity and...

Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding PipelinePETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial results and...

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product...

The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ("FDA") Approval of D-PLEX .The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial;...